Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.

ABSTRACT:

Importance

The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure were excluded. Men with mCRPC and seizure risk factors have an estimated seizure rate of 2.8 per 100 patient-years without enzalutamide exposure.

Objective

To assess seizure incidence in patients with seizure risk factors who were receiving enzalutamide for mCRPC.

Design, setting, and participants

The UPWARD study (A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide) is an international, mult

SUBMITTER: Slovin S 

PROVIDER: S-EPMC6145657 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature